About Myriad Oncology

Our goal is to make a difference in these patients’ lives by providing accurate information they can rely on when decisions matter most.

Myriad Oncology is a division of Myriad Genetics, Inc., a world leader in hereditary cancer testing with over 25 years of experience and over 3 million patients tested. Myriad Oncology focuses on providing answers for patients diagnosed with cancer or individuals who may have an inherited risk of developing cancer based on personal and family medical history.

All of Myriad Oncology's solutions:

Myriad Oncology’s suite of tests answer pressing questions related to 11 cancer types: Breast, Ovarian, Colorectal, Uterine, Skin, Pancreatic, Gastric, Prostate, Renal, Lung, and Endocrine.

About product signature

MyRisk Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.

Learn more

MyRisk Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.

Learn more

About product signature

Precise Tumor is a next-generation sequencing (NGS) assay with hybrid capture model consisting of DNA- and RNA-based testing which detects Single-Nucleotide Variants (SNV), Insertion-Deletion Mutations (INDELs), Copy Number Variants (CNV), and fusions in solid tumors.

Learn more

Precise Tumor is a next-generation sequencing (NGS) assay with hybrid capture model consisting of DNA- and RNA-based testing which detects Single-Nucleotide Variants (SNV), Insertion-Deletion Mutations (INDELs), Copy Number Variants (CNV), and fusions in solid tumors.

Learn more

About product signature

Making a decision on treatment options for patients diagnosed with early-stage breast cancer is an important choice and one that should be made with the best information possible. EndoPredict® can help accurately determine an individual patient’s 10-year risk of recurrence to help physicians identify which patients may consider safely forgoing chemotherapy.

Learn more

Making a decision on treatment options for patients diagnosed with early-stage breast cancer is an important choice and one that should be made with the best information possible. EndoPredict® can help accurately determine an individual patient’s 10-year risk of recurrence to help physicians identify which patients may consider safely forgoing chemotherapy.

Learn more

About product signature

BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).1,2,3

Learn more

BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).1,2,3

Learn more

About product signature

MyChoice® CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status.

Learn more

MyChoice® CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status.

Learn more

About product signature

Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.

Learn more

Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.

Learn more

Affordability

Myriad believes in affordable testing for patients who meet guidelines for testing. Through excellent insurance coverage and programs such as the Myriad Financial Assistance Program, providers and patients can feel confident knowing Myriad has multiple options tailored to each patient’s situation.

Accuracy

Myriad Oncology believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answer possible.

With our hereditary cancer tests, we make a lifetime commitment to patients to ensure that information does not stop after the results are delivered. As the science of genetics continues to evolve, Myriad is constantly reviewing and evaluating new developments, and any new findings that may impact patients are always delivered to both the provider and patient to maintain the highest quality of patient care possible.

Safe and secure

Myriad Oncology believes that results and genetic information belongs to the patient. We take several steps to ensure that the security and privacy of patient data is not compromised. We believe that patients should be in control of their information.

Simple, actionable results

Myriad Oncology knows that the field of genetics can be complex, but we have taken steps to ensure that both providers and patients are able to understand the results and further treatment options based on national medical guidelines. The MyRisk Medical Management Tool enables patients to share this vital information with their families in order to have all of your loved ones aware of any potential risks they may face. Patients who receive a test from Myriad Oncology can feel empowered to know that their results can be a meaningful piece of developing a prevention or treatment plan.